| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
4-Nitrophenylboronic acid has been shown to inhibit the enzyme protein tyrosine phosphatase 1B (PTP1B). PTP1B is a key regulator of insulin signaling, and its inhibition is a validated target for the treatment of type 2 diabetes and obesity. By inhibiting PTP1B, the compound may enhance insulin sensitivity and glucose uptake. It also serves as a building block for HIV protease inhibitors with antiviral activities.
|
|---|---|
| ln Vitro |
4-Nitrophenylboronic acid is an arylboronic acid that has found application in the phenolic synthesis process.
In vitro, 4-nitrophenylboronic acid is primarily used as a biochemical reagent and research tool. It serves as a key compound for studying carbohydrate recognition, enzyme inhibitors, and other biological interactions. As a PTP1B inhibitor, it can be used in enzyme inhibition assays to study insulin signaling pathways. The compound is also used as a reagent in Suzuki-Miyaura cross-coupling reactions for the synthesis of biologically active molecules. |
| ln Vivo |
In vivo data for 4-nitrophenylboronic acid as a therapeutic agent are limited. As a PTP1B inhibitor, it may have potential for the treatment of type 2 diabetes and obesity, but specific in vivo efficacy studies are not well-documented. The compound's in vivo relevance is primarily indirect, through the biological activities of the final pharmaceutical compounds derived from it, such as HIV protease inhibitors.
|
| Enzyme Assay |
For in vitro enzyme inhibition assays, 4-nitrophenylboronic acid is evaluated for PTP1B inhibitory activity. Standard protocols involve incubating the compound with recombinant PTP1B enzyme and measuring enzyme activity using a chromogenic or fluorogenic substrate (e.g., p-nitrophenyl phosphate). The compound (0.01-100 µM) is pre-incubated with the enzyme for 5-10 minutes at 25°C before substrate addition. IC₅₀ values are calculated from dose-response curves to quantify inhibitory potency.
|
| Cell Assay |
For in vitro cell-based experiments, 4-nitrophenylboronic acid can be evaluated for its effects on insulin signaling. Cells such as hepatocytes or adipocytes are treated with the compound at various concentrations (typically 0.1-100 µM) for 1-24 hours, then stimulated with insulin. Insulin signaling is assessed by measuring phosphorylation of the insulin receptor and downstream targets (e.g., AKT) by western blot. Glucose uptake assays using 2-deoxyglucose can also be performed.
|
| Animal Protocol |
In vivo animal studies for 4-nitrophenylboronic acid are limited. For potential antidiabetic candidates derived from this compound, efficacy studies would typically be performed in mouse models of type 2 diabetes (e.g., db/db or high-fat diet-fed mice). Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with measurement of blood glucose, insulin sensitivity, and body weight. Specific protocols for this compound are not well-documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-nitrophenylboronic acid are not extensively characterized. The compound has a molecular weight of 166.93 g/mol, which is favorable for oral bioavailability. As a boronic acid, it may be subject to metabolic oxidation. The compound's nitrophenyl group may influence its lipophilicity and permeability. Empirical pharmacokinetic data such as half-life, clearance, volume of distribution, and oral bioavailability are not available in the public literature.
|
| Toxicity/Toxicokinetics |
4-Nitrophenylboronic acid is a research chemical and should be handled with appropriate laboratory safety precautions. As a boronic acid derivative, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| References |
|
| Additional Infomation |
4-Nitrophenylboronic acid (CAS 24067-17-2) is primarily a research-grade chemical intermediate and biochemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as a PTP1B inhibitor for diabetes research, as a building block for HIV protease inhibitors, and as a reagent in Suzuki-Miyaura cross-coupling reactions. The compound is also used in studying carbohydrate recognition and enzyme inhibitors. No clinical trials or approved indications exist for this compound.
|
| Molecular Formula |
C6H6BNO4
|
|---|---|
| Molecular Weight |
166.93
|
| Exact Mass |
167.038
|
| CAS # |
24067-17-2
|
| PubChem CID |
2773552
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
373.7±44.0 °C at 760 mmHg
|
| Melting Point |
285-290°C (dec.)
|
| Flash Point |
179.8±28.4 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.574
|
| LogP |
1.32
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
161
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
B(C1=CC=C(C=C1)[N+](=O)[O-])(O)O
|
| InChi Key |
NSFJAFZHYOAMHL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6BNO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4,9-10H
|
| Chemical Name |
(4-nitrophenyl)boronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~200 mg/mL (~1198.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (29.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (29.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (29.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9905 mL | 29.9527 mL | 59.9053 mL | |
| 5 mM | 1.1981 mL | 5.9905 mL | 11.9811 mL | |
| 10 mM | 0.5991 mL | 2.9953 mL | 5.9905 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
